MAR 15, 2018 10:30 AM PDT

Overcoming Hurdles in the Study of Rare Diseases: Innovative Strategies for Novel Therapy Development

Presented at: Neuroscience 2018
Speaker
  • Senior Director of Therapeutic Development and Associate Scientist in Children's Health Research Center, Sanford Research
    Biography
      Dr. Jill Weimer is a developmental neuroscientist and oversees the management and continued development of the Children's Health Research Center at Sanford Research in Sioux Falls, South Dakota. She started at Sanford Research in 2009 as an associate scientist, and her research program focuses on the division and differentiation of neural stem cells in the developing brain and how disruption in these processes can lead to a whole host of neural pediatric disorders, including Batten's disease.

      Dr. Weimer grew up in north central Missouri and moved to upstate New York where she received her bachelor's degree and Ph.D. in neuroscience from the University of Rochester. She completed her postdoctoral training in the Neuroscience Research Center at the University of North Carolina in Chapel Hill with a focus on developmental neuroscience.

      Dr. Weimer is also very active in education and the community. In addition to her role at Sanford Research, she is an associate professor at the University of South Dakota Sanford School of Medicine and South Dakota State University's Department of Chemistry and Biochemistry. She co-founded The Sanford PROMISE (Program for the Midwest Initiative in Science Exploration) and the It's All About Science Festival. Dr. Weimer serves on a number of educational/community boards including for the South Dakota Innovative Lab and the Kirby Science Discovery Center and the Washington Pavilion's Board of Trustees. Her husband Jarrett works as a nuclear engineer for Exelon Power.

    Abstract

    The study of rare, neurological disorder and the development of effect treatments can pose many unique challenges. A paucity of scientists working on these disorders often limits forward progress on these disease and restricts access to good animals models, patient cells lines, and other tools for studying these disorders and can significantly hinder the speed at which treatments are developed for these disorders. In the last year, a number of groups have started to focus on how to transform "transdisciplinary" research in rare diseases to increase data sharing and expedite therapeutic development.  In this talk, we will use our work on a  rare, genetic, lysosomal storage disorder called CLN6-Batten disease as a case example of how to tackle rare disease research in a more efficient manner.  CLN6- Batten disease presents with gradual declines in motor, visual, and cognitive ability and early death by 12-15 years of age and currently no cures are available for this disease. CLN6-Batten disease is caused by mutations causing absence or reduced abundance of the CLN6 protein, making gene therapy a promising therapeutic strategy. We developed a scAAV9 vector expressing the human CLN6 (hCLN6) gene under the control of a chicken β-actin (CB) promoter. A single, postnatal intracerebroventricular (ICV) injection of scAAV9.CB.CLN6 at postnatal day 1 induced widespread, long-term expression of hCLN6 RNA and protein in the brain of Cln6nclf mice. This one-time treatment prevented or drastically reduced all of the pathological and behavioral hallmarks of Batten disease. Importantly, while all untreated CLN6 mice died between 12-14 months of age, scAAV9.CB.CLN6 significantly extended the median survival beyond 22 months of age and all of the histopathological, behavioral and cognitive parameters continued to improve throughout the lifespan of the treated mice. To our knowledge, this is the longest survival extension reported in this mouse model to date.


    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    DEC 16, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 16, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: December 16, 2020 Time: 8:00am (PST), 11:00am (EST) Molecular imaging of living specimens offers a means to draw upon the growing body of high-throughput molecular data to better under...
    SEP 02, 2020 7:00 AM PDT
    C.E. CREDITS
    SEP 02, 2020 7:00 AM PDT
    DATE: September 2, 2020 TIME: 03:00pm PDT, 6:00pm EDT Spatial omics is an expanding collection of methods to examine biological molecules in their geographical context. By retaining the prec...
    Loading Comments...
    Show Resources
    Attendees
    • See more